{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:44:04Z","timestamp":1787003044720,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008071","name":"Glaucoma Research Society of Canada","doi-asserted-by":"publisher","award":["000000"],"award-info":[{"award-number":["000000"]}],"id":[{"id":"10.13039\/100008071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008071","name":"Glaucoma Research Society of Canada","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008071","name":"Glaucoma Research Society of Canada","doi-asserted-by":"publisher","award":["000000"],"award-info":[{"award-number":["000000"]}],"id":[{"id":"10.13039\/100008071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41433-024-03574-4","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T01:25:53Z","timestamp":1735262753000},"page":"1160-1164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk of glaucoma with bisphosphonate use in patients with osteoporosis: a case-control study"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-4436","authenticated-orcid":false,"given":"Bonnie","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahyar","family":"Etminan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7125-230X","authenticated-orcid":false,"given":"Rami","family":"Darwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brennan","family":"Eadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"3574_CR1","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311:1901\u201311.","journal-title":"JAMA"},{"key":"3574_CR2","volume":"11","author":"N Zhang","year":"2021","unstructured":"Zhang N, Wang J, Li Y, Jiang B. Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review. Sci Rep. 2021;11:13762.","journal-title":"Sci Rep"},{"key":"3574_CR3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ajo.2020.04.020","volume":"218","author":"TM Kuang","year":"2020","unstructured":"Kuang TM, Xirasagar S, Kao YW, Shia BC, Lin HC. Association of systemic hypertension with primary open-angle glaucoma: a population-based case-control study. Am J Ophthalmol. 2020;218:99\u2013104.","journal-title":"Am J Ophthalmol"},{"key":"3574_CR4","first-page":"6","volume":"2015","author":"EY Ah-Kee","year":"2015","unstructured":"Ah-Kee EY, Egong E, Shafi A, Lim LT, Yim JL. A review of drug-induced acute angle closure glaucoma for non-ophthalmologists. Qatar Med J. 2015;2015:6.","journal-title":"Qatar Med J"},{"key":"3574_CR5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ceo.12763","volume":"45","author":"YC Tham","year":"2017","unstructured":"Tham YC, Cheng CY. Associations between chronic systemic diseases and primary open angle glaucoma: an epidemiological perspective. Clin Exp Ophthalmol. 2017;45:24\u201332.","journal-title":"Clin Exp Ophthalmol"},{"key":"3574_CR6","doi-asserted-by":"publisher","unstructured":"Fogel HA, Jenis LG. The economic burden of osteoporosis. In: Razi AE, Hershman SH, editors. Vertebral compression fractures in osteoporotic and pathologic bone: a clinical guide to diagnosis and management. Cham: Springer International Publishing; 2020. p. 21\u20139. Available from: https:\/\/doi.org\/10.1007\/978-3-030-33861-9_3.","DOI":"10.1007\/978-3-030-33861-9_3"},{"key":"3574_CR7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"T S\u00f6zen","year":"2017","unstructured":"S\u00f6zen T, \u00d6z\u0131\u015f\u0131k L, Ba\u015faran N\u00c7. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4:46\u201356. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28293453.","journal-title":"Eur J Rheumatol"},{"key":"3574_CR8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00198-012-2056-0","volume":"24","author":"MR McClung","year":"2013","unstructured":"McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, et al. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporos Int. 2013;24:293\u20139.","journal-title":"Osteoporos Int"},{"key":"3574_CR9","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1517\/14656566.2.9.1461","volume":"2","author":"TJ Schnitzer","year":"2001","unstructured":"Schnitzer TJ. Update on alendronate for osteoporosis: once-weekly dosing. Expert Opin Pharmacother. 2001;2:1461\u201372.","journal-title":"Expert Opin Pharmacother"},{"key":"3574_CR10","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s10067-010-1486-3","volume":"29","author":"M Maricic","year":"2010","unstructured":"Maricic M. The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol. 2010;29:1079\u201384.","journal-title":"Clin Rheumatol"},{"key":"3574_CR11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2147\/OPTH.S22429","volume":"5","author":"A Khan","year":"2011","unstructured":"Khan A, Lascaratos G, Rane-Malcolm T, Sanders R. A rare case of zolendronate infusion complication leading to glaucoma filtration surgery. Clin Ophthalmol. 2011;5:1147\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21887097.","journal-title":"Clin Ophthalmol"},{"key":"3574_CR12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/ICB.0000000000000850","volume":"15","author":"ZX Thng","year":"2021","unstructured":"Thng ZX, Li ZK, Gan NY. Bisphosphonate-induced bilateral anterior uveitis and choroidal effusions with secondary angle closure. Retin Cases Brief Rep. 2021;15:552\u20135.","journal-title":"Retin Cases Brief Rep"},{"key":"3574_CR13","unstructured":"IQVIA. chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.greygreenmedia.com\/app\/uploads\/sites\/2\/2020\/09\/IQVIA-PharMetrics-Plus-US-Fact-Sheet.pdf. 2020. IQVIA PharMectrics Plus Fact sheet."},{"key":"3574_CR14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00002018-200629020-00005","volume":"29","author":"B Aurich-Barrera","year":"2006","unstructured":"Aurich-Barrera B, Wilton L, Harris S, Shakir SAWhttps:\/\/pubmed.ncbi.nlm.nih.gov\/16454542\/. Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England. Drug Saf. 2006;29:151\u201360. [cited 2022 Oct 9] Available from: .","journal-title":"Drug Saf"},{"key":"3574_CR15","first-page":"837","volume":"117","author":"JN Mbekeani","year":"1999","unstructured":"Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL. Ocular inflammation associated with alendronate therapy. Arch Ophthalmol [Internet]. 1999;117:837\u20138. [cited 2022 Oct 9] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10369603\/.","journal-title":"Arch Ophthalmol [Internet]"},{"key":"3574_CR16","doi-asserted-by":"crossref","first-page":"E431","DOI":"10.1503\/cmaj.111752","volume":"184","author":"M Etminan","year":"2012","unstructured":"Etminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. CMAJ Can Med Assoc J. 2012;184:E431\u20134. May 15","journal-title":"CMAJ Can Med Assoc J"},{"key":"3574_CR17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1358\/dot.2003.39.11.799461","volume":"39","author":"FW Fraunfelder","year":"2003","unstructured":"Fraunfelder FW. Ocular side effects associated with bisphosphonates. Drugs Today. 2003;39:829\u201335. [cited 2022 Oct 9] Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/14702129\/.","journal-title":"Drugs Today"},{"key":"3574_CR18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamaophthalmol.2016.2166","volume":"134","author":"MA Pimentel","year":"2016","unstructured":"Pimentel MA, Browne EN, Janardhana PM, Borkar DS, Tham VM, Uchida A, et al. Assessment of the accuracy of using ICD-9 codes to identify uveitis, herpes zoster ophthalmicus, scleritis, and episcleritis. JAMA Ophthalmol. 2016;134:1001\u20136.","journal-title":"JAMA Ophthalmol"},{"key":"3574_CR19","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamaophthalmol.2018.3001","volume":"136","author":"AG Palestine","year":"2018","unstructured":"Palestine AG, Merrill PT, Saleem SM, Jabs DA, Thorne JE. Assessing the precision of ICD-10 codes for uveitis in 2 electronic health record systems. JAMA Ophthalmol. 2018;136:1186\u201390.","journal-title":"JAMA Ophthalmol"},{"key":"3574_CR20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.survophthal.2023.02.007","volume":"68","author":"LF Nakayama","year":"2023","unstructured":"Nakayama LF, Ribeiro LZ, Dychiao RG, Zamora YF, Regatieri CVS, Celi LA, et al. Artificial intelligence in uveitis: a comprehensive review. Surv Ophthalmol. 2023;68:669\u201377.","journal-title":"Surv Ophthalmol"},{"key":"3574_CR21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/01.ijg.0000195931.40664.3f","volume":"15","author":"D Paikal","year":"2006","unstructured":"Paikal D, Yu F, Holland GN, Coleman AL. Coding of glaucoma for patients with uveitis in the medicare database. J Glaucoma. 2006;15:13\u20136.","journal-title":"J Glaucoma"},{"key":"3574_CR22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/jcsm.12289","volume":"9","author":"HC Chiu","year":"2018","unstructured":"Chiu HC, Chiu CY, Yang RS, Chan DC, Liu SH, Chiang CK. Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation. J Cachexia Sarcopenia Muscle. 2018;9:585\u2013602.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3574_CR23","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.2147\/DDDT.S328858","volume":"15","author":"CF Huang","year":"2021","unstructured":"Huang CF, Shiao MS, Mao TY. Retrospective study of the effects of zoledronic acid on muscle mass in osteoporosis patients. Drug Des Dev Ther. 2021;15:3711\u20135.","journal-title":"Drug Des Dev Ther"},{"key":"3574_CR24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11914-020-00612-4","volume":"18","author":"EO Billington","year":"2020","unstructured":"Billington EO, Reid IR. Benefits of bisphosphonate therapy: beyond the skeleton. Curr Osteoporos Rep. 2020;18:587\u201396.","journal-title":"Curr Osteoporos Rep"},{"key":"3574_CR25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2008.10.043","volume":"602","author":"L Wu","year":"2009","unstructured":"Wu L, Zhu L, Shi WH, Zhang J, Ma D, Yu B. Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. Eur J Pharm. 2009;602:124\u201331.","journal-title":"Eur J Pharm"},{"key":"3574_CR26","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2147\/DDDT.S103124","volume":"10","author":"MZ Arun","year":"2016","unstructured":"Arun MZ, Reel B, Sala-Newby GB, Bond M, Tsaousi A, Maskell P, et al. Zoledronate upregulates MMP-9 and -13 in rat vascular smooth muscle cells by inducing oxidative stress. Drug Des Dev Ther. 2016;10:1453\u201360.","journal-title":"Drug Des Dev Ther"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03574-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03574-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03574-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:18:33Z","timestamp":1744204713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03574-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3574"],"URL":"https:\/\/doi.org\/10.1038\/s41433-024-03574-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3291076\/v1","asserted-by":"object"}]},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}